On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Initiates Patient Dosing in Phase I/IIa Combination Study Targeting Advanced Breast Cancer

  • Patient dosing has commenced in a combination study of Bria-IMT with KEYTRUDA or YERVOY in advanced breast cancer
  • Company recently announced positive proof of concept data in the Phase I/IIa study of Bria-IMT in advanced breast cancer patients, which indicated excellent targeted anti-tumor activity and outstanding safety and tolerability
  • KEYTRUDA and YERVOY are highly recognized for their potent immune boosting properties, which validates BriaCell’s strategy to use these therapeutics in its combination study

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company engaged in developing targeted and safe approaches for cancer management, recently announced (http://ibn.fm/Hej9T) that it has initiated patient dosing in a Phase I/IIa study of Bria-IMT, its lead clinical candidate, in combination with pembrolizumab (KEYTRUDA, which is manufactured by Merck & Co., Inc. [NYSE: MRK]) or ipilimumab (YERVOY, which is manufactured by Bristol-Myers Squibb Company [NYSE: BMY]). This combination study is listed on ClinicalTrials.gov as NCT03328026.

BriaCell continues its commitment to exploring new methods of addressing the advanced breast cancer community’s unmet medical needs, and the company is eager to test this novel combination treatment approach and believes that it will offer significant clinical benefits to patients who have advanced breast cancer.

Bria-IMT is essentially a breast cancer cell line that has been engineered to produce an immune-activating factor (GM-CSF) and has been shown to stimulate T-cells, which are vital cells within the immune system. Earlier this year, BriaCell published these findings in a leading immunology journal (http://ibn.fm/XicgM). Based on Bria-IMT’s published, proposed mechanism of action, BriaCell anticipates that Bria-IMT, combined with immune checkpoint inhibitors, can exert additive or synergistic tumor-directed effects resulting in even more potent anti-cancer immune responses and leading to the company’s strategy of combination studies of Bria-IMT with KEYTRUDA or YERVOY. It is important to note that pembrolizumab and ipilimumab have not been shown to work independently in breast cancer but are each approved for other indications.

On September 26, BriaCell announced positive proof of concept data in a phase I/IIa study of Bria-IMT in advanced breast cancer, which resulted in outstanding safety and efficacy in patients with HLA matches with Bria-IMT. An impressive point to note is that the safety and efficacy data appeared superior to that of other advanced or approved drugs for breast cancer when they were at a similar clinical development stage.

Analysis of blood samples collected in the phase I/IIa study showed that circulating tumor-associated cells expressed the immune checkpoint molecule programmed death-ligand 1 (PD-L1). PD-L1 molecules block immune cells from attacking cancer cells. KEYTRUDA neutralizes the blocking mechanism of PD-L1, while YERVOY blocks other aspects of immune suppression and, therefore, may also activate the immune system to destroy cancer cells.

Bria-IMT with KEYTRUDA or YERVOY Combination Study Details

  • KEYTRUDA Combination: Patients with expression of PD-L1 or PD-L2 on their cancer will be treated with the combination of Bria-IMT and the anti-PD-1 antibody KEYTRUDA.
  • YERVOY Combination: Patients without expression of PD-L1 or PD-L2 on their cancer will be treated with the combination of Bria-IMT and YERVOY, which is also expected to enhance the immune response induced by Bria- IMT.

It is hypothesized by the BriaCell team that patients in the combination therapy trial may receive particular benefit from these combinations with Bria-IMT.

Bria-IMT with KEYTRUDA or YERVOY Combination Study Rationale

Immune checkpoint inhibitors like pembrolizumab (KEYTRUDA; anti-PD-1) and ipilimumab (YERVOY; anti-CTLA-4), which are designed to overcome immune suppression in cancer patients, have become forerunners in the fight against cancer, offering substantial benefits for certain patients. The significance of immune checkpoint inhibitors was most recently recognized by the Nobel committee in awarding the 2018 Nobel Prize in Physiology or Medicine to Dr. Tasuku Honjo (PD-1) and Dr. James P. Allison (CTLA-4) (http://ibn.fm/pZKh4). This greatly validated BriaCell’s decision to launch a combination therapy with immune checkpoint inhibitors.

An important preclinical study conducted in 2010 by Dr. Allison’s group showed that combination with anti-PD-1 and anti-CTLA-4 antibodies potentiated the tumor-rejection effect of irradiated melanoma cells engineered to produce immune-activating factors.

BriaCell envisions that Bria-IMT and immune checkpoint inhibitors can exert additive or synergistic tumor-directed effects. In a recent interview, company CEO Dr. William Williams discussed the company’s immunotherapies in detail, and how the company is building offerings for the $30 billion immunotherapy market (http://ibn.fm/9D4Wk).

For more information, visit the company’s website at www.BriaCell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered